<?xml version="1.0"?>

<document>
	<title>Complement activation and pulmonary inflammation in CF patients.</title>

	<author>Schiotz-P-O.</author>
	<author>Sorensen-H.</author>
	<author>Hoiby-N.</author>

	<source>Monogr-Paediatr. 1979. 10. P 131-4.</source>

	<abstract>This study examined whether biologic activation of C3 with subsequent
   pulmonary inflammation takes place in the lungs of patients with
   cystic fibrosis.  Plasma complement C3 levels were all normal.
   Eleven of the patients with the C3 split product C3c were from the
   group of 14 patients suffering from chronic infection with mucoid
   strains of Pseudomonas aeruginosa and 2 were from the group of 14 CF
   patients without P. aeruginosa infection.  This difference was
   significant (p &lt; 0.002).  A comparison of albumin ratios between the
   13 patients with the C3 split product C3c and the remaining other 15
   patients showed a significant higher ratio in the former group (p &lt;
   0.01) on an average 4.1 versus 1.4 per cent.  The significantly
   higher albumin ratio demonstrated in the patients with C3c in their
   sputum sol phase supports the concept of complement-induced
   inflammation with subsequent transudation of plasma proteins in these
   patients.  This study thus shows that complement-mediated
   inflammatory reactions may play an important role in the pathogenesis
   of pulmonary tissue damage in patients with CF, even when the plasma
   C3 levels are normal, and it supports the concept of chronic P.
   aeruginosa lung infection as an immune complex disease in CF
   patients.</abstract>

	<majorsubject>COMPLEMENT-3: an</majorsubject>
	<majorsubject>CYSTIC-FIBROSIS: im</majorsubject>
	<majorsubject>LUNG: im</majorsubject>
	<majorsubject>PNEUMONIA: im</majorsubject>

	<minorsubject>HUMAN</minorsubject>
	<minorsubject>INFLAMMATION</minorsubject>
	<minorsubject>LUNG: pa</minorsubject>

	<reference>001   BROGAN TD             THORAX                          30    72 975</reference>
	<reference>002   CONOVER JH            LANCET                           2  1501 973</reference>
	<reference>003   GEWURTZ H             J EXP MED                      128  1049 968</reference>
	<reference>004   GIBSON LE             PEDIATRICS                      23   545 959</reference>
	<reference>005   GREENBLATT J          INFECT IMMUN                    19   296 978</reference>
	<reference>006   GOTZ M                EUR J PEDIATR                  127   133 978</reference>
	<reference>007   HANN S                LANCET                           2   520 974</reference>
	<reference>008   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974</reference>
	<reference>009   HOIBY N               SCAND J RESPIR DIS              58    65 977</reference>
	<reference>010   LAURELL CB            SCAND J CLIN LAB INVEST SUPPL  124    21 972</reference>
	<reference>011   LIEBERMAN J           AM REV RESPIR DIS              111   100 975</reference>
	<reference>012   MCFARLANE H           BR MED J                         1   423 975</reference>
	<reference>013   NELSON RA JR          IN: ZWEIFACH BW                  3    37 974</reference>
	<reference>014   SCANLIN TF JR         LANCET                           1  1382 974</reference>
	<reference>015   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   83   469 975</reference>
	<reference>016   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   86    37 978</reference>
	<reference>017   TEISBERG P            CLIN CHIM ACTA                  62    35 975</reference>
	<reference>018   WEEKE B               DAN MED BULL                    23   155 976</reference>

	<citation>1   HODSON ME             THORAX                          35   801 980</citation>
	<citation>2   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982</citation>

</document>
